title: Advances with RNA interference in Alzheimer's disease research.
abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized clinically by memory and cognitive dysfunction. Unfortunately, there is no effective therapeutic method for AD treatment or ways to halt disease progression. Many mechanisms are involved in the disease, including genes mutation and protein dysfunction. RNA interference (RNAi) technology may potentially be able to control AD. It can inhibit the protein expression of specific genes by activating a sequence-specific RNA degradation process. This is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we highlight the advances in RNAi technology in the investigation and treatment of AD.
authors: Department of Neurology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Jiaotong University, Shanghai.
authors: Shun
authors: S
authors: Chen
authors: Xuemei
authors: X
authors: Ge
authors: Yinghui
authors: Y
authors: Chen
authors: Nan
authors: N
authors: Lv
authors: Zhenguo
authors: Z
authors: Liu
authors: Weien
authors: W
authors: Yuan
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D000818:Animals; D001483:Base Sequence; D018450:Disease Progression; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D012313:RNA / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage*
chemical_list: D034741:RNA, Small Interfering; D012313:RNA
keywords: RNAi; amyloid precursor protein; tau; â-amyloid